Dynavax to Present at the 7th Annual Evercore HealthCONx Conference

DVAX 11.26.2024

SERA-AI Powered Highlights
Drug:Hepatitis B Vaccine (Recombinant), Adjuvanted HEPLISAV-B®
Drug:CpG 1018 CpG 1018®
Diseases:Hepatitis B
Date of Upcoming Event:2024-12-03
Name of Upcoming Event:7th Annual Evercore HealthCONx Conference
Full Press ReleaseSEC FilingsOur DVAX Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
  • 12.03.2024 - 7th Annual Evercore HealthCONx Conference
  • 11.26.2024 - Dynavax to Present at the 7th Annual Evercore HealthCONx Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 11.14.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors

EMERYVILLE, Calif.,Nov. 26, 2024/PRNewswire/ --Dynavax Technologies Corporation(Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th AnnualEvercore HealthCONx ConferenceonTuesday, December 3at2:35 p.m. ET.

(PRNewsfoto/Dynavax Technologies)

The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website athttps://investors.dynavax.com/events-presentations.

AboutDynavaxDynavaxis a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in theU.S., theEuropean UnionandGreat Britainfor the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. For more information about our marketed products and development pipeline, visitwww.dynavax.com.

For Investors/Media:Paul Coxpcox@dynavax.com510-665-0499

Nicole Arndtnarndt@dynavax.com510-665-7264

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-7th-annual-evercore-healthconx-conference-302315117.html

SOURCEDynavax Technologies

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com